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Dissociated statesThis issue of Sleep Science contains an article by Yeh and
Schenck about behavioral dyscontrol during sleep emerging
with sporadic (non-familial) nocturnal frontal lobe epilepsy
(NFLE) [1]. A series of eight cases was reported, with video-
polysomnography (vPSG) and sleep EEG documentation, and
successful treatment outcome [1]. The sporadic form of NFLE
is not as frequently reported and not as well understood
compared to familial, autosomal dominant NFLE. Two nota-
ble ﬁndings in this case series are that (i) the spectrum of
clinical features of sporadic NFLE, including its therapy,
closely match the well-known clinical features and therapy
of familial NFLE; and that (ii) the spectrum of clinical features
of sporadic NFLE, including its therapy, in this ﬁrst published
series in Asian patients (from Taiwan), closely match the
extensive published ﬁndings in Caucasian patients with
NFLE, as cited in the article. The challenging issue of distin-
guishing NFLE from nocturnal temporal lobe epilepsy (NTLE),
and from NREM sleep parasomnias is also addressed in this
article, with the pertinent literature cited. There are over-
lapping features of behavioral dyscontrol in sleep with these
three conditions, which very likely reﬂect overlapping activa-
tions of central (motor) pattern generators (CPGs) in the
brainstem [2]. Sleep related nocturnal dissociative disorder
(Noc DD) also shares behavioral features with these condi-
tions, and activation of CPGs was strongly suggested in one
reported case in which a 19 y.o. male engaged in prolonged(for several minutes) constant leg pedaling, both at home
and in the sleep laboratory, with both episodes captured on
video [3].
It is now known that abnormal ambulation during sleep
can be a manifestation of sleepwalking (SW), NFLE, NTLE,
REM sleep behavior disorder (RBD), or Noc DD [3–5]. Likewise,
screaming during sleep can be a manifestation of these same
conditions [6]. So in regards to similar abnormal complex
sleep behaviors, there is a broad range of causes and usually
separate therapies, which places a premium on establishing
the proper diagnosis, which can then direct appropriate
therapy. To this end, the validated Frontal Lobe Epilepsy
Parasomnias (FLEP) scale, developed by Derry et al. [7], has
been particularly useful in distinguishing NFLE from NREM
sleep parasomnias, as utilized in the Yeh and Schenck report
[1]. Nevertheless, controversial points are still being debated,
as the recognized difﬁculties “in distinguishing nocturnal
epileptic seizures from parasomnias reﬂect just one aspect
of the intriguing issue of the pathophysiological relationships
between all types of paroxysmal motor behaviors during
sleep” [8]. The complexity of these pathophysiological rela-
tionships is highlighted by a study ﬁnding a greatly increased
rate of NREM sleep arousal parasomnias in families of
patients with NFLE [9]. Research on the cyclic alternating
pattern (CAP), an EEG marker of arousal ﬂuctuations during
sleep, calls attention to the unifying role of pathological
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leptic, parasomnia and other abnormal motor events during
sleep [10]. A recent study found different CAP characteristics
in patients with NREM sleep arousal parasomnias compared
to patients with frontal and temporal lobe epilepsies [11],
which encourages further research on identifying different
CAP proﬁles across patient populations with behavioral dis-
turbances during sleep.Update on sleepwalking and other NREM sleep
parasomnias
Traditional knowledge regarding NREM sleep parasomnias as
being exclusively disorders of slow-wave sleep (SWS) and
disorders of arousal (DOA) from SWS, without either asso-
ciated dreaming, any recall of NREM parasomnia events, or
any daytime clinical concomitants, is giving way to an
updated, data-based perspective and new pathophysiological
hypotheses that are considered to represent a “paradigm
shift” in understanding SW and other DOA [12]. For example,
there is growing evidence suggesting that excessive daytime
sleepiness is part of the SW phenotype that is linked to its
underlying pathophysiology, and which cannot be explained
by any comorbid sleep disorder or PSG evidence of nocturnal
sleep disruption [13–15]. Also, in adult SW there can be
substantial recall of speciﬁc elements of SW episodes and
also recall of associated dreammentation, in striking contrast
to childhood SW [13]. These ﬁndings also highlight current
knowledge that SW is an expression of simultaneously
activated states of (partial) sleep and (partial) wakefulness,
a complex dissociated state, with clinical consequences [13].
These partially activated states of sleep and wakefulness
reﬂect regional brain activity of “local sleep” or of local
wakefulness. The concept of sleep as a whole-brain phenom-
enon has thus been radically reconsidered. In the new frame-
work, parasomnias, as clinical dissociated states, result from
coactivations of sleep and wakefulness across different brain
regions [16]. As stated by Zadra et al. in regards to the
pathophysiology of SW, “a broad and unifying view might
implicate the simultaneous activation of localized cortical
and subcortical networks that have roles in sleep and wake-
fulness [13]”.
A study on intracerebral EEG recording during sleep
documented a dissociation of regional EEG activities during
a parasomnia episode, illustrating how the brain phenom-
enon of “local sleep” can be the substrate for clinical dis-
sociated states [17]. In this study, a young adult male with
refractory focal epilepsy had a CA recorded by vPSG and
intracerebral EEG. The dissociated state underlying the CA
episode consisted of local arousal of the motor and cingulate
cortices that contrasted with simultaneous increased slow
waves in the frontoparietal associative cortices. These ﬁnd-
ings were present before the onset of the CA episode and
throughout the CA. Therefore, this carefully documented CA
episode was not a global sleep phenomenon, but rather a
phenomenon of coexisting and contrasting local states of
sleep and wakefulness.
A new clinical frontier for achieving a deeper understand-
ing of NREM sleep parasomnias and other sleep disorders hasbeen opened up by the use of high-density (256 electrode
channels) sleep EEG monitoring during vPSG studies, devel-
oped by the Tononi group. In a recent study utilizing high-
density sleep EEG in six healthy subjects [18], a total of 141
falling-asleep periods were analyzed to assess changes in
slow-wave and spindle activity during this transitional state.
The major ﬁnding was that the number and amplitude of
slow waves followed two dissociated, intersecting courses
during the wake-sleep transition: slow wave number
increased slowly at the beginning and rapidly at the end of
the falling-asleep period, whereas amplitude at ﬁrst
increased rapidly and then decreased linearly. Most slow
waves occurring early in the transition to sleep had a large
amplitude, a steep slope, and involved broad regions of the
cortex. Most slow waves occurring later had a smaller
amplitude and slope, and involved more circumscribed parts
of the cortex. Spindles were initially sparse, fast, and involved
few cortical regions, then became more numerous and
slower, and involved more areas. The two types of slow
waves identiﬁed in the wake-sleep transition had distinct
cortical origins and distributions. The authors hypothesized
that these two types of slow waves result from two distinct
synchronization processes: (1) a subcortico-cortical, arousal
system-dependent, process that predominates in the early
phase and leads to “type I slow waves”, and (2) a “horizontal”,
cortico-cortical synchronization process that predominates in
the late phase and leads to “type II slow waves”. The authors
concluded that the dissociation between these two slow-
wave synchronization processes in time and (brain) space
suggests that they could become pathologically disturbed
with sleep disorders – including NREM sleep parasomnias
that emerge from slow-wave sleep.
Other promising future research areas that could lead to a
deeper understanding of NREM sleep parasomnias include
various brain imaging techniques (including SPECT, PET,
transcranial magnetic stimulation), and familial, genetic,
and molecular studies that should provide additional critical
information on the neurobiological substrate of NREM sleep
parasomnias [13].Update on RBD
The “RBD odyssey” [19] continues at an accelerated pace
while covering ever-expanding territories of research. The
literature on RBD has continued to grow exponentially, both
in breadth and depth since the exponential growth of RBD
publications was ﬁrst quantiﬁed [20]. The most compelling
research, conducted by numerous international investigators,
concerns the strong associations of RBD with neurodegen-
erative disorders, especially the alpha-synucleinopathies, viz.
Parkinson disease (PD) dementia with Lewy bodies (DLB), and
Multiple System Atrophy (MSA) [21,22]. There are two per-
spectives for considering this strong association. First, RBD
can be the ﬁrst clinical manifestation of future alpha-
synucleinopathy neurodegeneration. Data from our center
and from the Barcelona group have recently documented 81%
and 82% “conversion rates”, respectively, from idiopathic RBD
(iRBD) to a parkinsonian disorder, with a mean interval of
approximately 12–14 years from onset of iRBD to the clinical
E d i t o r i a l / S l e e p S c i e n c e 7 ( 2 0 1 4 ) 1 2 9 – 1 3 4 131emergence of parkinsonism and/or dementia [23,24]. Second,
RBD has a strong presence in established neurodegenerative
disorders: 90–100% in MSA, approximately 75% in DLB, and up
to nearly 50% in PD [21]. The pathogenesis for how RBD can
emerge before, during or after the emergence of an alpha-
synucleinopathy has been proposed [22].
The presence of RBD in PD is associated with more
widespread disease across multiple dimensions of PD (e.g.
motor and cognition dysfunction, visual hallucinations,
deteriorated quality of life, etc.), compared to PD without
RBD, as documented in numerous studies. Furthermore, a
recent study has extended this ominous association by
reporting a very high predictive value of RBD in PD for
future PD-related dementia (PDD) [25]. In this study, 80 PD
patients without dementia had assessments of autonomic
nervous system, sleep, visual, olfactory, and motor func-
tioning at baseline. After 4.4 year follow-up, patients were
evaluated for dementia. Of these 80 patients, 27 (34%)
developed dementia. The presence of RBD at baseline
dramatically increased dementia risk (Odds Ratio¼49.7,
p¼0.001). In contrast, neither daytime sleepiness nor
insomnia predicted dementia.
The intersection of the ﬁelds of psychiatry, psychophar-
macology, RBD and neurodegeneration has been the focus of
attention in two recent publications [26,27]. Postuma et al.
tested for neurodegeneration markers in 73 unmedicated
iRBD patients, 27 iRBD patients taking antidepressants, and
45 controls [26]. The iRBD patients taking antidepressants,
compared to controls, had signiﬁcant abnormalities in 12/14
neurodegenerative markers – olfaction, color vision, UPDRS II/
III, alternate tap test, systolic BP drop, constipation, mild
cognitive impairment, etc. All these abnormalities were
indistinguishable in severity from iRBD patients not taking
antidepressants. However, on prospective follow-up, iRBD
patients taking antidepressants had a signiﬁcantly lower risk
of developing neurodegenerative disease compared to iRBD
patients not taking antidepressants: 22% vs. 59% 5-year risk.
The most reasonable explanation for this unpredicted ﬁnding
is that development of RBD with antidepressants can be an
early signal of an underlying neurodegenerative disorder. In
other words, in patients already at risk for alpha-neurode-
generation, antidepressant use accelerates the emergence of
RBD (which is very common in alpha-neurodegeneration)
without accelerating the clinical emergence of alpha-
neurodegeneration. The presence of RBD, irrespective of
antidepressant use, was strongly linked to the presence of
neurodegeneration markers. Presumably, the antidepressant-
induced RBD patients already had REM sleep-without-atonia
as a risk factor for RBD, but they were also presumably less
advanced in their progression to neurodegeneration than
iRBD patients not taking antidepressants. The ﬁve year
neurodegenerative disease conversion risk supports this
conclusion.
Wing et al. [27] address an important question raised by the
Postuma et al. study [26], viz. to what extent is RBD and major
depressive disorder (MDD), or the antidepressant medication
therapy of MDD, related to the prodromal phase of future alpha-
synuclein neurodegeneration? The case-control study of adults
o50 years old included 11 medicated patient with combined
RBD–MDD, 8 medicated patients with MDD alone, and 10 healthycontrols. They underwent clinical assessments, vPSG, neuropsy-
chological testing, and neuroimaging studies. Compared to the
other two groups, patients with combined RBD–MDD had
signiﬁcantly lower 18F-DOPA uptake in the putamen and
caudate at 60 min, after controlling for age and gender effects.
18F-DOPA uptake in the putamen had a signiﬁcant inverse
correlation with both the severity of RBD and the extent of
loss of REM-atonia. This group also had signiﬁcantly lower Ki
of the putamen compared to the two other groups. The
combined RBD–MDD group had impaired olfaction compared
to the other two groups, as the only other clinical sign
suggesting neurodegeneration. The authors concluded that
patients with combined RBD–MDD had presynaptic dopamine
dysfunction and olfactory dysfunction. This suggests that the
emergence of RBD in MDD patients (mainly in the 40–50 year
age range) may represent a prodromal phase of alpha-
synucleinopathy neurodegeneration, rather than RBD being
merely an antidepressant side effect in the therapy of MDD.
It should be noted that SSRIs and SNRIs were the antidepres-
sants used in all but two cases, which is in line with
published ﬁndings on antidepressant medication-induced
RBD. Large-scale studies are clearly needed to further con-
ﬁrm, reﬁne and expand the provocative ﬁndings from
this study.
It is evident that RBD is situated at a strategic and busy
crossroad of clinical (sleep) medicine and the neurosciences.
RBD offers great breadth and depth of research opportunities,
including extensive inter-disciplinary and multi-national
research opportunities [20]. To this end, the International
RBD Study Group (IRBD-SG) was founded and legally incor-
porated in Marburg, Germany. The IRBD-SG comprises a
network of leading basic science and clinical RBD researchers,
with the purpose of promoting international scientiﬁc
research and education on RBD and its related ﬁelds, and
optimizing medical care for afﬂicted patients by improving
diagnostic and therapeutic measures. The IRBD-SG has so far
held eight research symposia, in Marburg (2007, 2008, 2011),
Montreal (2010), Otsu City, Japan (2011), and Paris (2012),
Valencia (2013) and Helsinki (2015). Given the relatively low
number of patients with RBD identiﬁed at individual RBD
research centers, a major focus of the IRBD-SG is to facilitate
multicenter studies.
To date, six IRBD-SG studies have been published in peer-
reviewed journals [28–33], the notable ﬁndings of which will
now be summarized, together with a seventh collaborative
group study that involved many members of the IRBD-SG [34].
In an environmental risk factor study [28], patients with iRBD
who were free of dementia and parkinsonism were recruited
from 13 centers. Controls were matched according to age and
sex. Potential environmental and lifestyle risk factors were
assessed via standardized questionnaire. A total of 694
participants (347 patients, 347 controls) were recruited. Com-
pared to controls, RBD patients were signiﬁcantly more likely
to have been smokers, and to have had head injury, pesticide
exposure, and worked as farmers, and so it was concluded
that these comprised risk factors for iRBD.
A second study tested a single screening question for RBD
[29]. 242 RBD iRBD patients and 242 controls were given a
screening question about dream-enactment, with a yes/no
response option. All patients and controls had undergone
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RBD diagnosis (in the controls). There was a 93.8% sensitivity
and 87.2% speciﬁcity to this single question, which compared
favorably to reports on longer RBD screening questionnaires.
A third study devised controlled active treatment studies
for symptomatic and neuroprotective therapies, which also
represented a consensus statement by the IRBD-SG [30]. This
publication serves to anticipate the arrival of promising
neuroprotective, or disease-modifying, therapies to be tested
in double-blind fashion in newly-diagnosed iRBD patients.
However, it is currently not known when such promising
agents will be identiﬁed for testing. This remains the most
pressing and challenging issue in the convergent ﬁelds of RBD
and PD.
A fourth study investigated the frequency of proxy-
reported RBD (viz. dream-enactment) among relatives of
patients with vPSG-conﬁrmed iRBD [31]. A total of 316
patients and 316 controls were recruited from 12 IRBD-SG
centers. A positive family history of dream enactment was
reported in 13.8% of iRBD cases compared to 4.8% of controls
(odds ratio [OR]¼3.9, 95% conﬁdence interval [CI] 2.0–7.7). ORs
were increased for both siblings and parents. These ﬁndings
suggest a possible genetic contribution to RBD. However, a
limitation of this study was the lack of vPSG studies (to
conﬁrm or exclude RBD) in the ﬁrst-degree relatives.
A ﬁfth study addressed the topic of comorbidity and
medication use in iRBD patients, in a multi-center case-
control study [32]. Patients with iRBD were signiﬁcantly more
likely to report depression and concomitant antidepressant
use (predominantly SSRIs). Patients with iRBD also reported
signiﬁcantly more ischemic heart disease, after adjusting for
cardiovascular risk factors.
A sixth study addressed autonomic symptoms in iRBD
[33]. The study was encouraged by knowledge that patients
with iRBD are at very high risk of developing neurodegenera-
tive synucleinopathies, which are disorders with prominent
autonomic dysfunction. Patients with vPSG-conﬁrmed iRBD
(318 cases) and 318 controls were recruited from 13 neurolo-
gical centers in 10 countries. A validated scale to study the
disorders of the autonomic nervous system in Parkinson's
disease (PD) patients, the SCOPA-AUT, was administered to
all the patients and controls. Patients with iRBD experienced
signiﬁcantly more problems with gastrointestinal, urinary,
and cardiovascular functioning. The most prominent differ-
ences in severity of autonomic symptoms between our iRBD
patients and controls emerged in the gastrointestinal
domain. Interestingly, it has been reported that an altered
gastrointestinal motility, with clinical complaints of consti-
pation, can predate the motor phase of PD. These ﬁndings
underscore the importance of collecting data on autonomic
symptoms in iRBD patients.
A seventh study sought to determine the pathologic
substrates in patients with RBD with or without a coexisting
neurologic disorder [34]. Clinical and neuropathologic ﬁnd-
ings were analyzed on all autopsied RBD cases from collabor-
ating sites in North America and Europe. 172 RBD cases were
identiﬁed (83% male). The primary clinical diagnoses among
those with a coexisting neurologic disorder were DLB (n¼97),
PD with or without mild cognitive impairment or dementia
(n¼32), MSA (n¼19), Alzheimer's disease (AD) (n¼9) andother various disorders (n¼3). The neuropathologic diagnoses
were Lewy body disease (LBD) (n¼77), combined LBD and AD
(n¼59), MSA (n¼19), AD (n¼6), progressive supranulear palsy
(PSP) (n¼2), and other disorders (n¼9). The key ﬁnding was
that among the neurodegenerative disorders associated with
RBD (n¼170), 160 (94%) were synucleinopathies. Furthermore,
the RBD–synucleinopathy association was particularly high
when RBD preceded the onset of other neurodegenerative
syndrome features.
An indication of the currently regarded importance of RBD
research is exempliﬁed by a regular issue of the journal
“Sleep Medicine [2013; 14(8)]” being devoted exclusively to
RBD. In that issue, there were 18 peer-reviewed papers
covering basic and clinical science topics related to RBD,
including original research and review articles.
Finally, Brazilian investigators have broken new ground
with RBD research in at least three directions: (i) Wilson's
disease (hepatolenticular degeneration) presenting with RBD
as the initial symptom [35], which comprises the ﬁrst pub-
lished description of RBD in Wilson's disease in the literature,
and adds further evidence to the parallelism of PD and
Wilson's disease in phenotype and brainstem topography.
(ii) Cannabidiol (CBD) therapy in RBD associated with PD [36].
CBD is the main non-psychotropic component of the Canna-
bis sativa plant. Four patients with RBD-PD treated with CBD
had prompt and substantial reduction in the frequency of
RBD-related events, without side effects. (iii) A new category
of Parasomnia Overlap Disorder (i.e. RBD combined with a
NREM parasomnia [37]) was identiﬁed, consisting of Sleep
Related Eating Disorder combined with RBD-PD [38].Conclusion
The current, rapidly-evolving knowledge on the NREM sleep
parasomnias, nocturnal seizures and RBD reﬂects the bene-
ﬁcial interplay of the ﬁelds of neuroscience and clinical
(sleep) medicine, which will continue to deepen as additional
neuroscientiﬁc tools become available. Parasomnias are
clearly embedded within the core of sleep medicine and
sleep science. One striking example consists of the many
parasomnias that can be associated with sleep-disordered
breathing and its therapy [39]. Other major examples consist
of the strong association of sleep related eating disorder with
RLS [40,41], and with narcolepsy [42]. Consequently, sleep
clinicians and clinical investigators are encouraged to
increase their interest and knowledge on the parasomnias,
and in so doing they can hopefully make useful and impor-
tant contributions to the ﬁeld, while enhancing patient care.
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